BioMarin (Phase III PARP)
M&A
STATUS
Asset Purch.
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Provider of drugs for the treatment of breast cancer. The company specializes in orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- 770 Lindaro Street
- San Rafael, CA 94901
- United States
BioMarin (Phase III PARP) Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore BioMarin (Phase III PARP)‘s full profile, request access.
Request full access to PitchBookBioMarin (Phase III PARP) Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore BioMarin (Phase III PARP)‘s full profile, request access.
Request full access to PitchBook